Korea's Celltrion SVP Kim Hyoung-Ki On Gearing Up To Launch Biosimilars In Global Markets: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Up until a few years ago, South Korea's biosimilar front-runner Celltrion Inc.'s main business was manufacturing products for others. But the company inked a deal with U.S.-based Hospira in 2009 to collaborate on manufacturing and marketing eight biosimilars. Celltrion has hinted that a bigger deal with Hospira could be in the works, which would provide the Korean company with a global sales network.
You may also be interested in...
Celltrion Files For Korea Approval Of Herceptin Biosimilar
Amid M&A talks and expectations for imminent European approval of a Remicade biosimilar, Celltrion becomes the first company to file for regulatory approval of a biosimilar of Roche’s blockbuster breast cancer therapy trastuzumab.
On Heels of Remsima Launch, Celltrion Gears Up For Herceptin Biosimilar Approval In Korea
Following the start of sales of Remsima, a biosimilar of J&J’s Remicade, Celltrion is moving to begin selling its Herceptin biosimilar in Korea this year. It will be Celltron’s second biosimilar on the market.
Korea’s Samsung Biologics Halts Rituxan Biosimilar Trials To Meet U.S, EU Standards
Samsung Biologics halts ongoing clinical trials across 16 countries for its Rituxan biosimilar as it seeks clarity on emerging regulatory guidelines by U.S. FDA.